HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $60 Price Target
CRINETICS PHARMACEUTICALS, INC. -1.40% Pre
CRINETICS PHARMACEUTICALS, INC. CRNX | 57.15 57.15 | -1.40% 0.00% Pre |
HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:
CRNX) with a Buy and maintains $60 price target.